Estrella Immunopharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company that develops CD19- and CD22-targeted ARTEMIS T-cell therapies to treat blood cancers, solid tumors and autoimmune diseases. The company focuses on its proprietary ARTEMIS platform, licensed from parent Eureka Therapeutics, Inc., featuring lead candidate EB103 in Phase I of the STARLIGHT-1 trial for relapsed/refractory diffuse large B-cell lymphoma and B-cell non-Hodgkin’s lymphoma; EB104 in preclinical development targeting both CD19 and CD22 for diffuse large B-cell lymphoma and acute lymphocytic leukemia; EB201 in preclinical stage for systemic lupus erythematosus; and combination therapies such as EB103 with oncolytic virus CF33-CD19t for solid tumors via collaborative agreements with Eureka Therapeutics and Imugene Limited. Founded in 2022 as a Delaware corporation and headquartered at 5858 Horton Street, Suite 370, Emeryville, California, Estrella completed a business combination with TradeUp Acquisition Corp. in September 2023 to become publicly listed on Nasdaq Capital Market in October 2023; it recently raised approximately $3.35 million in a private investment in public equity financing in May 2025 to advance the STARLIGHT-1 Phase I trial of EB103 and initiated the second dose cohort while dosing the first patient in the study.
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells